

## Borderline personality disorder

Klaus Lieb, Mary C Zanarini, Christian Schmahl, Marsha M Linehan, Martin Bohus

Borderline personality disorder is characterised by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships, and self-image. Clinical signs of the disorder include emotional dysregulation, impulsive aggression, repeated self-injury, and chronic suicidal tendencies, which make these patients frequent users of mental-health resources. Causal factors are only partly known, but genetic factors and adverse events during childhood, such as physical and sexual abuse, contribute to the development of the disorder. Dialectical behaviour therapy and psychodynamic partial hospital programmes are effective treatments for out-of-control patients, and drug therapy can reduce depression, anxiety, and impulsive aggression. More research is needed for the understanding and management of this disabling clinical condition. Current strategies are focusing on the neurobiological underpinnings of the disorder and the development and dissemination of better and more cost-effective treatments to clinicians.

Borderline personality disorder is a serious mental disorder with a characteristic pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships, and self-image. It affects about 1–2% of the general population—up to 10% of psychiatric outpatients, and 20% of inpatients.<sup>1–3</sup> The disorder is characterised by severe psychosocial impairment<sup>4</sup> and a high mortality rate due to suicide—up to 10% of patients commit suicide, a rate almost 50 times higher than in the general population.<sup>5</sup> Because of substantial treatment use, patients with borderline personality disorder require more mental-health resources than do individuals with other psychiatric disorders.<sup>6,7</sup>

### Epidemiology

In epidemiological studies of adults, the weighted prevalence of borderline personality disorder ranges from 0.7% in Norway to 1.8% in the USA.<sup>1,2</sup> Additionally, findings from these studies showed that the disorder was more common in women than in men (about 70% and 30%, respectively), indicating the sex difference that is typical in treated-patients.<sup>3</sup> In a community-based sample of children and adolescents, the prevalence of borderline personality disorder was 11% at age 9–19 years and 7.8% at 11–21 years. This disorder was also more common in girls than boys,<sup>8</sup> but whether it is more frequent in children than adults is unknown owing to the study's reliance on a suboptimum assessment of symptoms.

### Diagnosis

The panel lists the nine diagnostic and statistical manual of mental disorders (DSM) IV criteria for borderline personality disorder—which in the international classification of diseases 10th revision is a subtype of emotionally unstable personality disorders. Here, we have organised these criteria into four sectors of psychopathology because patients who manifest symptoms in all four areas simultaneously can be successfully discriminated from those with other forms of personality disorder.<sup>9</sup>

The first area is affective disturbance. Patients with borderline personality disorder have a range of intense

dysphoric affects, sometimes experienced as aversive tension, including rage, sorrow, shame, panic, terror, and chronic feelings of emptiness and loneliness. These individuals can be distinguished from other groups by the overall degree of their multifaceted emotional pain.<sup>10,11</sup> Another aspect of their affective disturbance is their tremendous mood reactivity;<sup>12</sup> patients often move from one interpersonally reactive mood state to another, with great rapidity and fluidity, experiencing several dysphoric states and periods of euthymia during the course of one day.

Second is disturbed cognition. Patients show three levels of cognitive symptomatology:<sup>13</sup> (1) troubling but non-psychotic problems, such as overvalued ideas of being bad, experiences of dissociation in terms of depersonalisation and derealisation, and non-delusional suspiciousness and ideas of reference; (2) quasi-psychotic or psychotic-like symptoms—ie, transitory, circumscribed, and somewhat reality-based delusions and hallucinations; and (3) genuine or true delusions and hallucinations. The last category mostly happens in the context of psychotic depression.<sup>13,14</sup> Serious identity disturbance is thought to be in the cognitive realm because it is based on a series of false beliefs—eg, one is good one minute and bad the next.

Third is impulsivity. Patients engage in two types: deliberately physically self-destructive, and more general forms of impulsivity. Self-mutilation, suicidal communication, and suicide attempts are the constituent elements of the first type of impulsivity, and common forms of the second are substance abuse, disordered eating, spending sprees, verbal outbursts, and reckless driving.

Fourth is intense unstable relationships, which are characterised by two separate but interlocking types of

*Lancet* 2004; 364: 453–61

Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstrasse 5, D-79104 Freiburg, Germany (K Lieb MD); McLean Hospital and Harvard Medical School, Belmont, MA, USA (M C Zanarini EdD); Department of Psychosomatics and Psychotherapeutic Medicine, University of Heidelberg, Central Institute of Mental Health, Mannheim, Germany (C Schmahl MD, Prof M Bohus MD); and Department of Psychology, University of Washington, Seattle, WA, USA (Prof M M Linehan PhD)

Correspondence to: Klaus Lieb klaus\_lieb@psyallg.ukl.uni-freiburg.de

#### Search strategy and selection criteria

We searched MEDLINE for articles with the main search term “borderline personality disorder”. We chose articles relevant to the topics epidemiology, diagnosis, pathophysiology, psychotherapy, and pharmacotherapy, with special emphasis on randomised controlled trials.

**Panel: DSM-IV criteria for borderline personality disorder\*****Affective criteria**

- Inappropriate intense anger or difficulty controlling anger—eg, frequent displays of temper, constant anger, recurrent physical fights
- Chronic feelings of emptiness
- Affective instability due to a marked reactivity of mood—eg, intense episodic dysphoria, irritability, or anxiety usually lasting a few hours and only rarely more than a few days

**Cognitive criteria**

- Transient stress-related paranoid ideation or severe dissociative symptoms
- Identity disturbance: striking and persistent unstable self-image or sense of self

**Behavioural criteria (forms of impulsivity)**

- Recurrent suicidal behaviour, gestures, or threats, or self-mutilating behaviour
- Impulsivity in at least two areas that are potentially self-damaging that do not include suicidal or self-mutilating behaviour

**Interpersonal criteria**

- Frantic efforts to avoid real or imagined abandonment that do not include suicidal or self-mutilating behaviour
- A pattern of unstable and intense interpersonal relationships characterised by alternating between extremes of idealisation and devaluation

\*Five of nine criteria needed to diagnose borderline personality disorder

problem. The first is a profound fear of abandonment, which tends to manifest itself in desperate efforts to avoid being left alone—eg, calling people on the phone repeatedly or physically clinging to them. The second is a tumultuous quality to close relationships, which are marked by frequent arguments, repeated breakups, and reliance on a series of maladaptive strategies that can both anger and frighten others—eg, highly emotional or unpredictable responses.




Figure: Neurobehavioural model of borderline personality disorder

Patients with borderline personality disorder generally meet DSM criteria for other psychiatric illnesses. In terms of axis I disorders, major depression, substance misuse, post-traumatic stress disorder, other anxiety disorders, and eating disorders are all common in these individuals.<sup>15–18</sup> 41–83% of patients with borderline personality disorder report a history of major depression,<sup>16–18</sup> and lifetime prevalence of other common axis I disorders was 12–39% for dysthymia, 10–20% for bipolarity, 64–66% for substance misuse, 46–56% for post-traumatic stress disorder, 23–47% for social phobia, 16–25% for obsessive-compulsive disorder, 31–48% for panic disorder, and 29–53% for any eating disorder. In terms of axis II disorders, avoidant, dependent, and paranoid personality disorders are the most frequently diagnosed comorbid conditions.<sup>15,18,19</sup> Prevalence of these three disorders was 43–47%, 16–51%, and 14–30%, respectively.<sup>18,19</sup>

Careful clinical assessment of borderline personality disorder and possible comorbid conditions is important at the beginning of a patient's treatment. Semistructured diagnostic interviews are becoming more usual. Several measures are highly reliable in the care of these patients.<sup>20,21</sup>

**Causal factors**

The cause of borderline personality disorder is complex with several factors, which interact in various ways with each other (figure). Genetic factors and adverse childhood experiences might cause emotional dysregulation and impulsivity leading to dysfunctional behaviours and psychosocial conflicts and deficits, which again might reinforce emotional dysregulation and impulsivity.<sup>22</sup> Data for the role of genetic factors are sparse. In one twin study, based on DSM-IV criteria, concordance rates were seen for borderline personality disorder of 35% and 7% in monozygotic and dizygotic twin pairs, respectively, suggesting a strong genetic effect in the development of the disorder.<sup>23</sup> Multivariate genetic analyses of personality disorder traits have identified four factors, with the main one labelled as emotional dysregulation and describing labile affects, unstable cognitive functioning, an unstable sense of self, and unstable interpersonal relationships. This main factor resembles borderline personality disorder in many aspects, and heritability can be estimated at 47%.<sup>21,22,24</sup>

Various types of adverse events during childhood, including ongoing experiences of neglect and abuse, are reported by many patients.<sup>25–27</sup> The most frequent of these is childhood sexual abuse, which is reported by 40–71% of inpatients with borderline personality disorder.<sup>25–33</sup> The severity of borderline psychopathology has also been linked to severity of childhood sexual abuse.<sup>34,35</sup> Taken together, these findings have led some clinicians to view borderline personality disorder as a form of chronic post-traumatic stress disorder. However, no evidence is available that childhood sexual abuse is

either necessary or sufficient for development of this disorder. Other childhood factors have been judged important in development of the disorder, particularly difficulties attaining stable attachments.<sup>36</sup> However, a study of attachment styles of patients with borderline personality disorder noted that these individuals reported increased concern about losing their primary attachment figure.<sup>37</sup> In view of this slight empirical evidence, whether these attachment difficulties are causal or a result of the emotional turbulence and impulsivity associated with borderline personality disorder is not clear.

### Neurobiological findings

The neurobiological factors of borderline personality disorder, such as impulsivity and affect dysregulation, are poorly understood. In view of the heterogeneity of the disorder, workers have investigated distinct subgroups in search of different endophenotypes.<sup>21,22,38</sup> Furthermore, sex seems to have an important role in the neurobiology of this disorder. Several researchers have recorded substantial<sup>39–41</sup> differences between male and female patients with respect to serotonergic function.

Structural and functional neuroimaging has revealed a dysfunctional network of brain regions that seem to mediate important aspects of borderline personality disorder symptomatology. This dysfunctional fronto-limbic network consists of the anterior cingulate cortex (ACC), the orbitofrontal and dorsolateral prefrontal cortex, the hippocampus, and the amygdala. Findings of fluorodeoxyglucose-positron-emission-tomography studies have shown altered baseline metabolism in prefrontal regions including the ACC.<sup>42–44</sup> These brain areas also seem to have a role in dysfunctional serotonergic neurotransmission,<sup>45</sup> which has been associated with disinhibited impulsive aggression in patients with borderline personality disorder. Furthermore, a reduction of frontal and orbitofrontal lobe volumes<sup>46,47</sup> and N-acetyl-aspartate, a marker of neuronal integrity,<sup>48</sup> has been reported. In challenge studies with emotional and stressful stimuli, deactivation, or failure of activation, of the ACC has been shown in patients with borderline personality disorder.<sup>49,50</sup> Since the ACC can be viewed as a brain region mediating affective control, dysfunction in this area might be related to affective dysregulation, which is characteristic of the disorder.

Work in animals has established that the amygdala has a central role in emotional regulation.<sup>51</sup> In a study with an emotional stimulation paradigm combined with functional MRI (fMRI), an enhanced signal in the amygdala was recorded bilaterally in patients with borderline personality disorder compared with matched controls.<sup>52</sup> Donegan and colleagues<sup>53</sup> reported increased left amygdala activation in response to facial expression of negative emotions with fMRI. Results of structural imaging studies indicate reduced hippocampal and

amygdala volumes in patients with borderline personality disorder.<sup>47,54,55</sup> This finding of reduced hippocampal volume is consistent with many studies of post-traumatic stress disorder. Amygdala volume reduction, however, sets borderline personality disorder apart from post-traumatic stress disorder, in which the amygdala seems to be structurally unaffected. In the context of diminished volumes of stress-sensitive brain regions, such as the hippocampus, the cortisol system deserves attention. Rinne and co-workers<sup>56</sup> noted a hyper-responsiveness of the hypothalamic-pituitary-adrenal (HPA) axis in patients with borderline personality disorder and a history of sustained childhood abuse, lending support to the hypothesis of a relation between early traumatisation and increased HPA axis function in adulthood.

These neuroimaging findings seem to indicate that a weakening of prefrontal inhibitory control could contribute to amygdala hyperactivity. Simultaneous limbic and prefrontal disturbances suggest dual brain pathology as a neuropathological correlate of hyper-arousal-dyscontrol syndrome, seen in patients with borderline personality disorder. However, whether the observed neurobiological dysfunctions are pre-existing—ie, due to genetic, pre-postnatal factors, or adverse events during childhood—or the consequence of the disorder itself, is unknown.

### Treatment

Over their lifetime, 97% of patients with borderline personality disorder presenting for treatment in the USA receive outpatient care from an average of six therapists;<sup>57,58</sup> 95% receive individual therapy, 56% group therapy, 42% family or couples psychotherapy, 37% day treatment, 72% psychiatric hospitalisation, and 24% treatment in a halfway house. 9–40% of frequent users of inpatient psychiatric services are diagnosed with the disorder.<sup>3,59–62</sup>

Analyses of outcomes measured 2–3 years after treatment suggest that treatments-as-usual are marginally effective at best.<sup>63,64</sup> Even in those receiving a lot of psychosocial treatment and pharmacotherapy, there is probably severe impairment in employment, global satisfaction, social adjustment, and overall functioning.<sup>4</sup> Because public mental-health outpatient services have traditionally focused on the needs of patients with schizophrenia and bipolar disorder, these facilities might not meet the needs of individuals with borderline personality disorder, which could account for poor treatment compliance and subsequent hospitalisation.<sup>61,65</sup> The association of this disorder with attempted and completed suicide makes psychosocial interventions mandatory for severe cases, even when concomitant pharmacotherapy is applied. Between 40% and 65% of individuals who commit suicide meet criteria for a personality disorder, with borderline personality disorder being the most commonly associated.<sup>66</sup>

### Psychosocial interventions

Very few randomised controlled trials have assessed psychosocial interventions for borderline personality disorder, especially compared with the number of trials for other psychiatric disorders. Over the past 10 years, however, two structured psychotherapeutic programmes have emerged as effective interventions for this disorder. Both treatments target the highly dysfunctional and out-of-control patient. Of the two, a variation of cognitive behavioural therapy—dialectical behaviour therapy (DBT)—has the most empirical support from seven well-controlled trials (table 1).<sup>67–79</sup> Six non-randomised controlled studies have also been undertaken comparing DBT with ongoing treatment-as-usual.<sup>80–85</sup> DBT is based on a combined capability deficit and a motivational model of borderline personality disorder, which states that: individuals with this disorder do not have important interpersonal, self-regulation (including emotional regulation), and distress tolerance skills; and personal and environmental factors sometimes block and inhibit use of behavioural skills that patients have, and at times reinforce dysfunctional behaviours. DBT addresses five functions of comprehensive treatment: (1) it increases behavioural capabilities by teaching specific skills to regulate emotions, to tolerate emotional distress when change is slow or unlikely, to be more effective in interpersonal conflicts, and to control attention in order to skilfully participate in the moment; (2) it improves motivation to change by intensive behavioural analyses,

application of exposure-based treatment procedures, and management of reinforcement contingencies; (3) it ensures that new capabilities are useful for day-to-day life by various strategies, such as use of the telephone; (4) it structures the environment, particularly the treatment network, to reinforce patients' skilful behaviours; and (5) it enhances therapist capabilities and motivation by including a weekly meeting of therapists for support and consultation.

A psychodynamic long-term partial hospital programme has also been shown to be effective in a controlled study, although the results have not been replicated in a second trial nor tested by an independent research team.<sup>78,79</sup> Several other treatment approaches, such as transference-focused therapy,<sup>86</sup> are promising but in need of controlled trials.

Patients with borderline personality disorder enter treatment at various levels of severity: most serious are those who have severe behavioural dyscontrol. In these individuals the first priority is to increase behavioural control and reduce severely dysfunctional behaviours; the goal is to get the patient functioning and productive. With suicidal individuals, the first priority is to decrease life-threatening behaviours, particularly suicidal behaviours, and the level of suicidality should be actively and consistently monitored. Once the patient has achieved adequate behavioural control their intense dysphoria and difficulties managing emotional experiences emerge as the central target of therapy. Treatment at this stage will

Treatments (number of patients)	Inclusion criteria	Length of study	Main effects	Reference
DBT (n=24) versus community mental health TAU (n=22)	BPD + suicide attempt in last 8 weeks + one other in last 5 years Female	1 year	Frequency, medical risk, parasuicide (suicide attempts and intentional self-injury); treatment retention; use of emergency and inpatient treatment; anger, social and global adjustment	Linehan et al, 1991 <sup>67</sup> Linehan et al, 1993 <sup>68</sup> Linehan et al, 1994 <sup>69</sup> Linehan et al, 1993 <sup>70</sup>
DBT (n=12) versus community drug misuse/mental health TAU (n=16)	BPD + current drug dependence Female	1 year	Illicit drug use, social and global adjustment	Linehan et al, 1999 <sup>71</sup>
DBT + LAAM (n=11) versus comprehensive validation treatment (DBT without change strategies) + 12-step facilitation and 12-step group + LAAM (n=12)	BPD + current opiate dependence Female	1 year	Opiate use	Linehan et al, 2002 <sup>72</sup>
DBT (n=12) versus client-centred therapy (n=12)	BPD + referral from Emergency services for suicide attempt	1 year	Parasuicide (suicide attempts and self-injury), impulsiveness, anger, depression, global adjustment, use of inpatient treatment	Turner, 2000 <sup>73</sup>
DBT (n=10) versus veterans administration mental health TAU (n=10)	BPD Female	6 months	Parasuicide (suicide attempts and self-injury) frequency (trend), suicide ideation, hopelessness, depression, anger expression	Koons et al, 2001 <sup>74</sup>
DBT (n=31) versus community drug abuse/mental health TAU (n=33)	BPD Female	1 year	Frequency of self-mutilation and suicide attempts (trend), treatment retention, self-damaging impulsivity	Verheul et al, 2003 <sup>75</sup> Van den Bosch et al 2002 <sup>76</sup>
DBT (n=52) versus community treatment by psychotherapy experts in suicide and BPD (n=51)	BPD + parasuicide (suicide attempt or self-injury) in last 8 weeks + one other in last 5 years Female	1 year	Suicide attempts, suicidality, medical risk and risk/rescue rating of parasuicide (suicide attempts and self-injury), treatment retention, emergency and inpatient treatment, anger directed outward	Linehan et al, 2002 <sup>77</sup>
Psychoanalytic partial hospitalisation (n=19) versus TAU (no psychotherapy) (n=19)	BPD	1.5 years	Self-mutilation, suicide attempts, use of inpatient services, anxiety, depression, social and global adjustment	Bateman, Fonagy, 1999 <sup>78</sup> Bateman, Fonagy, 2001 <sup>79</sup>

DBT= dialectical behaviour therapy; BPD=borderline personality disorder; TAU=treatment-as-usual; LAAM=levro-alpha-acetylmethadol [A: Is this the RIIN]

**Table 1: Summary of randomised controlled trials of psychotherapy studies for treatment of borderline personality disorder**

focus most typically on reduction of experiential avoidance. The suggestion that borderline personality disorder patients do not make medically serious suicide attempts is untrue and, as noted above, the suicide rate in these individuals is very high. Pharmacotherapy or hospitalisation should not be assumed to be the treatment of choice for suicidality in these patients. Evidence that medication will reduce the risk of suicide or attempted suicide is scarce. Findings of randomised trials of DBT suggest that an intervention that emphasises treatment of suicidal behaviours on an aggressive outpatient basis, and only rarely hospitalises, can still show lower rates of suicide attempts than standard treatments that frequently refer patients to emergency services and for inpatient treatment.<sup>67,74,75,77</sup> Substantial evidence suggests that cognitive behavioural treatments focused on active problem solving, together with high therapeutic outreach and availability, will reduce the risk of suicidal behaviours.<sup>87</sup>

Patients with borderline personality disorder usually start their treatment meeting criteria for multiple axis I disorders, which vary over time in their severity and urgency. Effective treatment, therefore, integrates the full range of evidence-based behavioural treatments for axis I disorders. However, maintenance of a consistent focus on multiple serious maladaptive behaviour patterns without frequent changes in priorities can be difficult. With the more severe patients, in particular, the clinician must engage the patient in setting clear and explicit goals for therapy, prioritise their importance, and adhere to these treatment targets. Both DBT and Bateman and Fonagy's<sup>78,79</sup> treatments are multimodal; every modality of treatment targets a specific aspect of the patient's overall difficulty. In DBT, the individual psychotherapist serves as the primary therapist managing, with the patient, the

application of other treatment modalities. These treatments also balance the focus on change and the patient's responsibilities to actively engage in problem solving, with a corresponding focus on empathy, validation, and active therapeutic support. Finally, every treatment provides support for the therapists treating the patient. High suicidality in these patients and the difficulty in forming and maintaining a therapeutic alliance, together with a need to coordinate care among a diverse set of therapists and settings, sometimes creates enormous stress for therapists. Thus, therapists treating individuals with severe borderline personality disorder must also receive on-going supervision or consultation and honestly communicate their own personal limits to those they treat.

### Pharmacotherapy

High proportions of patients with this disorder are continuously taking medication, and rates of intensive polypharmacy are not uncommon and do not decline with time.<sup>88</sup> Results of placebo-controlled trials (table 2)<sup>89-100</sup> suggest that pharmacotherapy for borderline personality disorder could be used to target certain aspects, such as cognitive-perceptual symptoms, emotional dysregulation, or impulsive-behavioural dyscontrol.<sup>101,102</sup> In many patients, medication might not only calm the patients but also allow them to reflect before acting. This treatment might be relevant to psychosocial interventions, providing the possibility to discontinue medication once patients have learned to manage themselves.

Neuroleptics could be effective against cognitive-perceptual symptoms, such as suspiciousness, paranoid ideation, ideas of reference, or transitory (stress-related) hallucinations. Although placebo-controlled trials have reported mixed results, especially for haloperidol (table 2),

Drug	Number of patients given drug/placebo	Mean dose per day mg (SD)	Weeks of treatment	Main effects	Reference
Amitriptyline	20/20	148 (14)	5	Depression	Soloff et al, 1986 <sup>89</sup>
Tranlycypromine	16/16*	40 (fixed dose)	6	Depression, anger, impulsivity, suicidality	Cowdry, Gardner, 1988 <sup>90</sup>
Phenelzine	38/34	60.5 (10)	5	Anger/hostility	Soloff et al, 1993 <sup>91</sup>
Fluvoxamine	38/19	166 (27)	12	Rapid mood shifts	Rinne et al, 2002 <sup>92</sup>
Fluoxetine	9/8	20-60	12	Global measures, anger, anxiety	Markovitz, 1995 <sup>93</sup>
Fluoxetine	13/9	40	13	Anger	Salzman et al, 1995 <sup>94</sup>
Trifluoperazine	16/16*	7.8	6	Depression, anxiety, suicidality	Cowdry, Gardner, 1988 <sup>90</sup>
Thiothixene	25/25	8.7	12	Psychotic cluster symptoms, anxiety, obsessive-compulsive symptoms	Goldberg et al, 1986 <sup>95</sup>
Haloperidol	21/20	7.2 (3.2)	5	Depression, anxiety, hostility, psychoticism	Soloff et al, 1986 <sup>89</sup>
Haloperidol	36/34	3.9 (0.7)	5	..	Soloff et al, 1993 <sup>91</sup>
Olanzapine	19/9	5.3 (3.4)	26	Anxiety, anger/hostility, paranoia, interpersonal difficulties	Zanarini, Frankenburg, 2001 <sup>96</sup>
Carbamazepine	16/16*	820	6	Behavioural dyscontrol	Cowdry, Gardner, 1988 <sup>90</sup>
Carbamazepine	10/10	6.4-7.1 µg/mL†	4	..	De la Fuente, Lotstra, 1994 <sup>97</sup>
Valproic acid	12/4	..	10	Global measures (CGI-I)	Hollander et al, 2001 <sup>98</sup>
Valproic acid	20/10	850 (249)	26	Interpersonal sensitivity, aggression, anger/hostility	Frankenburg, Zanarini, 2002 <sup>99</sup>
Omega-3-fatty acid	20/10	1000	8	Aggression, depression	Zanarini, Frankenburg, 2003 <sup>100</sup>

\*Double-blind cross-over trial with placebo, tranlycypromine, trifluoperazine, carbamazepine, and alprazolam. †Blood concentration range.

**Table 2: Summary of placebo-controlled trials in the treatment of borderline personality disorder**

severity of schizotypal symptoms, hostility, and suspiciousness were predictors for a favourable response.<sup>95,102,103</sup> Atypical neuroleptics have been tested in the latest trials because of the risk of extrapyramidal side-effects including tardive dyskinesia. Open studies for clozapine,<sup>104,105</sup> risperidone,<sup>106</sup> and olanzapine<sup>107</sup> show good tolerability and efficacy of these substances. In a placebo-controlled trial, the atypical neuroleptic olanzapine was superior to placebo in the treatment of all four core sectors of borderline psychopathology.<sup>96</sup> Haloperidol had no effect in a 16-week continuation therapy.<sup>108</sup>

The prominence of emotional dysregulation, including rapid mood shifts, depressive symptoms and anxiety, dysphoria, intense anger, and chronic emptiness, suggests a role for antidepressants. Whereas early studies reported moderate effects of antidepressants, such as the tricyclic antidepressant amitriptyline<sup>99</sup> or the monoamine-oxidase inhibitor phenelzine<sup>91</sup> (table 2), later placebo-controlled studies have provided evidence for the efficacy of selective serotonin reuptake inhibitors (SSRIs) on rapid mood shifts, anger, and anxiety.<sup>92-94,109</sup> The possible toxic effects (eg, after overdose), the potential worsening of cognitive-perceptual symptoms by tricyclic antidepressants,<sup>89</sup> and the difficulties in managing borderline patients on monoamine-oxidase inhibitors could lead clinicians to consider SSRIs as first-line agents in the treatment of the depressed, anxious, labile, and angry patient.<sup>102</sup> Another option is mood stabilisers. Four placebo-controlled studies of these drugs, have reported mixed results for carbamazepine and valproic acid (table 2). Valproic acid could especially be suited for patients with a comorbid bipolar disorder<sup>99</sup> and for those with impulsive aggression in cluster B personality disorder.<sup>110</sup> For lamotrigine, no controlled trials are available, although, a case series has shown promising effects.<sup>111</sup> In a study of omega-3 fatty acids for the treatment of borderline personality disorder<sup>100</sup> the treatment seemed to be as effective as commercial mood stabilisers, and better compliance was achieved (low dropout rate) owing to the low side-effect burden and lack of stigma.

Although the impulsive-behaviour symptom domain, consisting of suicidal and parasuicidal behaviours, impulsive-aggression, and binge behaviours, might respond to psychotherapy SSRIs can be given as an adjuvant.<sup>112</sup> The latest approaches have focused on pharmacotherapy for specifically defined single symptoms, such as inner tension and dissociation, and preliminary evidence in open studies has shown efficacy of clonidine<sup>113</sup> and naltrexone,<sup>114</sup> respectively.

Interpretation of results from pharmacological studies should take into account several limitations. Drugs have mostly been tested in moderately ill outpatients, thus, to relate these study results to the most severely ill patient population is difficult. Moreover, studies are hampered by high drop-out rates because of difficulty in keeping patients with borderline personality disorder on

medication for sustained periods.<sup>96,98,115</sup> In several psychosocial and pharmacological treatment trials only female patients were investigated<sup>90,92,96,99,100</sup> making generalisation of effects to male patients difficult. Owing to low symptom stability over time in borderline personality disorder,<sup>116</sup> pharmacological studies are especially prone to high placebo response rates.<sup>94</sup> Results from open studies should, therefore, be interpreted with caution.

### Course and prognosis

Research suggests that borderline personality disorder, or at least some of its symptoms, begins in the late latency period of childhood but that treatment is typically not sought until late adolescence.<sup>6</sup> The disorder has a better prognosis than other serious mental illnesses, such as bipolar disorder.<sup>117,118</sup> In two large-scale prospective studies of the course of borderline personality disorder, symptoms have been noted to be less stable than previously recognised.<sup>116,119</sup> After 6 years' follow-up, about 75% of patients with the disorder, all of whom were hospitalised at the start of the study, achieved remission (according to Revised Diagnostic Interview for Borderlines [DIB-R] and DSM-III-R criteria).<sup>119</sup> Additionally, only 6% of those who achieved remission had a later recurrence. 4% of the patients committed suicide within the 6-year study period, despite the fact that about 80% had a history of suicide attempts at the time of their index admission. Notably, two earlier retrospective studies of the course of borderline personality disorder recorded suicide rates of 9–10%.<sup>120,121</sup> Additionally, no prospective data are available on outcome in borderline patients who are middle-aged or older.

Many factors are associated with poor outcome, including: affective instability and increased length of previous hospitalisations;<sup>122</sup> presence of dysphoria, family history of mental illness, younger age when first in treatment, and presence of maternal psychopathology,<sup>123,124</sup> and history of parental brutality.<sup>121</sup> Conversely, few factors are associated with a good outcome, including: high IQ (intelligence quotient);<sup>121,122</sup> absence of narcissistic entitlement or of parental divorce; and presence of self-destructive acts during the index admission.<sup>125</sup>

### Future prospects

Much still needs to be learned about borderline personality disorder. If the prodromal condition or the actual disorder first manifests itself in childhood or adolescence, early intervention and prevention strategies need to be developed. Irrespective of when the disorder first develops, current treatments are suboptimum, and better and more cost-effective treatments are needed. Until now, the most broadly effective treatments are the psychosocial interventions, especially DBT, which not only has a solid empirical basis but also has been widely accepted by both mental-health consumers and clinicians. As Swenson and colleagues have noted,<sup>126</sup> however,

despite DBT's appeal, implementation frequently requires acquisition of new skills. Very little research has been done on how to disseminate effective psychosocial interventions to the community of clinicians. With respect to pharmacotherapy, additional randomised controlled treatment trials are necessary. Such studies should investigate the potential usefulness of mood stabilisers, such as lamotrigine, new-generation antidepressants, or atypical neuroleptics. Furthermore, the benefits of polypharmacy should be tested since it is commonly used but has no empirical support. Also, possible additive effects of pharmacotherapy and psychotherapy, and treatment options for borderline personality disorder associated with comorbid axis I disorders, should be assessed. Clinicians have been reluctant to inform patients with borderline personality disorder of their diagnosis. This attitude is beginning to (and should) change since it allows such patients to become informed consumers of mental-health services. Finally, psychoeducation of the patients' families is very important since it enables them to become allies in the treatment of this disabling disorder.

**Conflict of interest statement**  
None declared.

#### Acknowledgments

M Bohus and K Lieb received grants from Borderline Personality Disorder Research Foundation and German Research Foundation (DFG Bo 1487-2; 1487-3; 1487-4), M Zanarini received grants from NIMH (MH47588 and MH62169), and M Linehan received grants from NIMH and NIDA (MH34486 and DA014997) and Borderline Personality Disorder Research Foundation. These sources of funding had no role in the preparation of this manuscript.

#### References

- Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. *Arch Gen Psychiatry* 2001; **58**: 590–96.
- Swartz MS, Blazer D, George L, Winfield I. Estimating the prevalence of borderline personality disorder in the community. *J Personal Disord* 1990; **4**: 257–72.
- Widiger TA, Weissman MM. Epidemiology of borderline personality disorder. *Hosp Comm Psychiatry* 1991; **42**: 1015–21.
- Skodol AE, Gunderson JG, McGlashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. *Am J Psychiatry* 2002; **159**: 276–83.
- American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder—introduction. *Am J Psychiatry* 2001; **158**: 2.
- Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. *Compr Psychiatry* 2001; **42**: 144–50.
- Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. *Am J Psychiatry* 2001; **158**: 295–302.
- Bernstein DP, Cohen P, Velez CN, Schwab-Stone M, Siever LJ, Shinsato L. Prevalence and stability of the DSM-III-R personality disorders in a community-based survey of adolescents. *Am J Psychiatry* 1993; **150**: 1237–43.
- Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. Discriminating borderline personality disorder from other axis II disorders. *Am J Psychiatry* 1990; **147**: 161–67.
- Zanarini MC, Frankenburg FR, DeLuca CJ, Hennen J, Khera GS, Gunderson JG. The pain of being borderline: dysphoric states specific to borderline personality disorder. *Harv Rev Psychiatry* 1998; **6**: 201–07.
- Stiglmayr CE, Shapiro DA, Stieglitz RD, Limberger MF, Bohus M. Experience of aversive tension and dissociation in female patients with borderline personality disorder: a controlled study. *J Psychiatr Res* 2001; **35**: 111–18.
- Koenigsberg HW, Harvey PD, Mitropoulou V, et al. Characterizing affective instability in borderline personality disorder. *Am J Psychiatry* 2002; **159**: 784–88.
- Zanarini MC, Gunderson JG, Frankenburg FR. Cognitive features of borderline personality disorder. *Am J Psychiatry* 1990; **147**: 57–63.
- Pope HG Jr, Jonas JM, Hudson JI, Cohen BM, Tohen M. An empirical study of psychosis in borderline personality disorder. *Am J Psychiatry* 1985; **142**: 1285–90.
- Oldham JM, Skodol AE, Kellman HD, et al. Comorbidity of axis I and axis II disorders. *Am J Psychiatry* 1995; **152**: 571–78.
- Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. *Am J Psychiatry* 1998; **155**: 1733–39.
- Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. *Compr Psychiatry* 1999; **40**: 245–52.
- McGlashan TH, Grilo CM, Skodol AE, et al. The Collaborative Longitudinal Personality Disorders Study: baseline axis I/II and II/II diagnostic co-occurrence. *Acta Psychiatr Scand* 2000; **102**: 256–64.
- Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis II comorbidity of borderline personality disorder. *Compr Psychiatry* 1998; **39**: 296–302.
- Zimmerman M. Diagnosing personality disorders: a review of issues and research models. *Arch Gen Psychiatry* 1994; **51**: 225–45.
- Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ, Siever LJ. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. *Biol Psychiatry* 2002; **51**: 936–50.
- Skodol AE, Siever LJ, Livesley WJ, Gunderson JG, Pfohl B, Widiger TA. The borderline diagnosis II: biology, genetics, and clinical course. *Biol Psychiatry* 2002; **51**: 951–63.
- Torgersen S, Lygren S, Per A, et al. A twin study of personality disorders. *Compr Psychiatry* 2000; **41**: 416–25.
- Livesley WJ, Jang KL, Vernon PA. Phenotypic and genetic structure of traits delineating personality disorder. *Arch Gen Psychiatry* 1998; **55**: 941–48.
- Zanarini MC, Gunderson JG, Marino MF, Schwartz EO, Frankenburg FR. Childhood experiences of borderline patients. *Compr Psychiatry* 1989; **30**: 18–25.
- Zanarini MC, Williams AA, Lewis RE, Reich RB. Reported pathological childhood experiences associated with the development of borderline personality disorder. *Am J Psychiatry* 1997; **154**: 1101–06.
- Links PS, Steiner M, Offord DR, Eppel A. Characteristics of borderline personality disorder: a Canadian study. *Can J Psychiatry* 1988; **33**: 336–40.
- Ogata SN, Silk KR, Goodrich S, Lohr NE, Westen D, Hill EM. Childhood sexual and physical abuse in adult patients with borderline personality disorder. *Am J Psychiatry* 1990; **147**: 1008–13.
- Paris J, Zweig-Frank H, Guzder J. Psychological risk factors for borderline personality disorder in female patients. *Compr Psychiatry* 1994; **35**: 301–05.
- Paris J, Zweig-Frank H, Guzder J. Risk factors for borderline personality in male outpatients. *J Nerv Ment Dis* 1994; **182**: 375–80.
- Shearer SL, Peters CP, Quayman MS, Ogden RL. Frequency and correlates of childhood sexual and physical abuse histories in adult female borderline inpatients. *Am J Psychiatry* 1990; **147**: 214–16.
- Westen D, Ludolph P, Mistle B, Ruffins S, Block J. Physical and sexual abuse in adolescent girls with borderline personality disorder. *Am J Orthopsychiatry* 1990; **60**: 55–66.
- Herman JL, Perry JC, van der Kolk BA. Childhood trauma in borderline personality disorder. *Am J Psychiatry* 1989; **146**: 490–95.
- Zanarini MC, Yong L, Frankenburg FR, et al. Severity of reported childhood sexual abuse and its relationship to severity of borderline psychopathology and psychosocial impairment among borderline inpatients. *J Nerv Ment Dis* 2002; **190**: 381–87.
- Silk KR, Lee S, Hill EM, Lohr NE. Borderline personality disorder symptoms and severity of sexual abuse. *Am J Psychiatry* 1995; **152**: 1059–64.

- 36 Gunderson JG. The borderline patient's intolerance of aloneness: insecure attachments and therapist availability. *Am J Psychiatry* 1996; **153**: 752–58.
- 37 West M, Keller A, Links P, Patrick J. Borderline disorder and attachment pathology. *Can J Psychiatry* 1993; **38** (suppl 1): S16–S22.
- 38 Siever LJ, Torgersen S, Gunderson JG, Livesley WJ, Kendler KS. The borderline diagnosis III: identifying endophenotypes for genetic studies. *Biol Psychiatry* 2002; **51**: 964–68.
- 39 Soloff PH, Kelly TM, Strotmeyer SJ, Malone KM, Mann JJ. Impulsivity, gender, and response to fenfluramine challenge in borderline personality disorder. *Psychiatry Res* 2003; **119**: 11–24.
- 40 Leyton M, Okazawa H, Diksic M, et al. Brain regional alpha-[C-11] Methyl-(L)-Tryptophan trapping in impulsive subjects with borderline personality disorder. *Am J Psychiatry* 2001; **158**: 775–82.
- 41 New AS, Hazlett EA, Buchsbaum MS, Goodman M, Koenigsberg HW, Iskander L. M-CPP PET and impulsive aggression in borderline personality disorder. *Biol Psychiatry* 2003; **53**: 104S.
- 42 De la Fuente JM, Goldman S, Stanus E, et al. Brain glucose metabolism in borderline personality disorder. *J Psychiatr Res* 1997; **31**: 531–41.
- 43 Soloff PH, Meltzer CC, Becker C, Greer PJ, Kelly TM, Constantine D. Impulsivity and prefrontal hypometabolism in borderline personality disorder. *Psychiatry Res* 2003; **123**: 153–63.
- 44 Juengling FD, Schmahl C, Hesslinger B, et al. Positron emission tomography in female patients with borderline personality disorder. *J Psychiatr Res* 2003; **37**: 109–15.
- 45 Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM. A fenfluramine-activated FDG-PET study of borderline personality disorder. *Biol Psychiatry* 2000; **47**: 540–47.
- 46 Lyoo IK, Han MH, Cho DY. A brain MRI study in subjects with borderline personality disorder. *J Affect Disord* 1998; **50**: 235–43.
- 47 Tebartz van Elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. *Biol Psychiatry* 2003; **54**: 163–71.
- 48 van Elst LT, Thiel T, Hesslinger B, et al. Subtle prefrontal neuropathology in a pilot magnetic resonance spectroscopy study in patients with borderline personality disorder. *J Neuropsych Clin Neurosci* 2002; **13**: 511–14.
- 49 Schmahl CG, Elzinga BM, Vermetten E, Sanislow C, McGlashan TH, Bremner JD. Neural correlates of memories of abandonment in women with and without borderline personality disorder. *Biol Psychiatry* 2003; **54**: 142–51.
- 50 Schmahl CG, Vermetten E, Elzinga BM, Bremner JD. A positron emission tomography study of memories of childhood abuse in borderline personality disorder. *Biol Psychiatry* 2004; **55**: 759–65.
- 51 Fanselow MS, Gale GD. The amygdala, fear, and memory. *Ann NY Acad Sci* 2003; **985**: 125–34.
- 52 Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. *Biol Psychiatry* 2001; **50**: 292–98.
- 53 Donegan NH, Sanislow CA, Blumberg HP, et al. Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. *Biol Psychiatry* 2003; **54**: 1284–93.
- 54 Driessen M, Herrmann J, Stahl K, et al. Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. *Arch Gen Psychiatry* 2000; **57**: 1115–22.
- 55 Schmahl CG, Vermetten E, Elzinga BM, Douglas BJ. Magnetic resonance imaging of hippocampal and amygdala volume in women with childhood abuse and borderline personality disorder. *Psychiatry Res* 2003; **122**: 193–98.
- 56 Rinne T, de Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. *Biol Psychiatry* 2002; **52**: 1102–12.
- 57 Skodol AE, Buckley P, Charles E. Is there a characteristic pattern to the treatment history of clinic outpatients with borderline personality? *J Nerv Ment Dis* 1983; **171**: 405–10.
- 58 Perry JC, Herman JL, van der Kolk BA, Hoke LA. Psychotherapy and psychological trauma in borderline personality disorder. *Psychiatric Annals* 1990; **20**: 33–43.
- 59 Geller JL. In again, out again: preliminary evaluation of a state hospital's worst recidivists. *Hosp Comm Psychiatry* 1986; **37**: 386–90.
- 60 Surber RW, Winkler EL, Monteleone M, Havassy BE, Goldfinger SM, Hopkin JT. Characteristics of high users of acute psychiatric inpatient services. *Hosp Comm Psychiatry* 1987; **38**: 1112–14.
- 61 Swigar ME, Astrachan B, Levine MA, Mayfield V, Radovich C. Single and repeated admissions to a mental health center: demographic, clinical and use of service characteristics. *Int J Soc Psychiatry* 1991; **37**: 259–66.
- 62 Woogh CM. A cohort through the revolving door. *Can J Psychiatry* 1986; **31**: 214–21.
- 63 Tucker L, Bauer SF, Wagner SC, Harlam D. Long-term hospital treatment of borderline patients: a descriptive outcome study. *Am J Psychiatry* 1987; **144**: 1443–48.
- 64 Perry JC, Cooper SH. Psychodynamics, symptoms, and outcome in borderline and antisocial personality disorders and bipolar type II affective disorder. In: McGlashan TH, ed. *The borderline: current empirical research*. Washington, DC: American Psychiatric Press, 1985; 21–41.
- 65 Rascati JN. Managed care and the discharge dilemma: commentary. *Psychiatry J Study Interpersonal Process* 1990; **53**: 124–26.
- 66 Linehan MM, Rizvi SL, Welch SS, Page B. Psychiatric aspects of suicidal behaviour: personality disorders. In: Hawton K, Van Heeringen K, eds. *International handbook of suicide and attempted suicide*. Sussex: John Wiley & Sons, 2000; 147–78.
- 67 Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. *Arch Gen Psychiatry* 1991; **48**: 1060–64.
- 68 Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. *Arch Gen Psychiatry* 1993; **50**: 971–74.
- 69 Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. *Am J Psychiatry* 1994; **151**: 1771–76.
- 70 Linehan MM, Heard HL. Impact of treatment accessibility on clinical course of parasuicidal patients: in reply to Hoffman RE. *Arch Gen Psychiatry* 1993; **50**: 158.
- 71 Linehan MM, Schmidt HI, Dimeff LA, Craft JC, Kanter J, Comtois KA. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. *Am J Addict* 1999; **8**: 279–92.
- 72 Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. *Drug Alcohol Depend* 2002; **67**: 13–26.
- 73 Turner RM. Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. *Cognit Behav Practice* 2000; **7**: 413–19.
- 74 Koons CR, Robins CJ, Tweed JL, et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. *Behav Ther* 2001; **32**: 371–90.
- 75 Verheul R, van den Bosch LMC, Koeter MWJ, De Ridder MAJ, Stijnen T, van den Brink W. Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in the Netherlands. *Br J Psychiatry* 2003; **182**: 135–40.
- 76 van den Bosch LM, Verheul R, Schippers GM, van den BW. Dialectical behavior therapy of borderline patients with and without substance use problems: implementation and long-term effects. *Addict Behav* 2002; **27**: 911–23.
- 77 Linehan MM, Comtois KA, Brown M, et al. DBT versus nonbehavioral treatment by experts in the community: clinical outcomes. Symposium presentation for the Association for Advancement of Behavior Therapy. University of Washington, Reno NV, 2002.
- 78 Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. *Am J Psychiatry* 1999; **156**: 1563–69.
- 79 Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. *Am J Psychiatry* 2001; **158**: 36–42.
- 80 Barley WD, Buie SE, Peterson EW, et al. Development of an inpatient

- cognitive-behavioral treatment program for borderline personality disorder. *J Personal Disord* 1993; 7: 232–40.
- 81 McCann RAB, Ball EM, Ivanoff A. DBT with an inpatient forensic population: the CMHIP forensic model. *Cognit Behav Practice* 2000; 7: 447–56.
  - 82 Stanley B, Ivanoff A, Brodsky BS, Oppenheim S. Comparison of DBT and treatment as usual in suicidal and self-mutilating behavior. Paper presented at the 32nd annual convention of the Association for the Advancement of Behavior Therapy. Washington, DC, November, 1998.
  - 83 Bohus M, Haaf B, Stiglmayr CE, Pohl U, Boehme R, Linehan MM. Evaluation of inpatient dialectical-behavioral therapy for borderline personality disorder: a prospective study. *Behav Res Ther* 2000; 38: 875–87.
  - 84 Bohus M, Haaf B, Simms T, et al. Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. *Behav Res Ther* 2004; 42: 487–99.
  - 85 Rathus JH, Miller AL. Dialectical behavior therapy adapted for suicidal adolescents. *Suicide Life Threat Behav* 2002; 32: 146–57.
  - 86 Clarkin JF, Foelsch PA, Levy KN, Hull JW, Delaney JC, Kernberg OF. The development of a psychodynamic treatment for patients with borderline personality disorder: a preliminary study of behavioral change. *J Personal Disord* 2001; 15: 487–95.
  - 87 Linehan MM. Behavioral treatments of suicidal behaviors. definitional obfuscation and treatment outcomes. *Ann N Y Acad Sci* 1997; 836: 302–28.
  - 88 Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. *J Clin Psychiatry* 2004; 65: 28–36.
  - 89 Soloff PH, George A, Swami N, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. *Arch Gen Psychiatry* 1986; 43: 691–97.
  - 90 Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and translycypromine. *Arch Gen Psychiatry* 1988; 45: 111–19.
  - 91 Soloff PH, Cornelius JR, George A, Nathan RS, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. *Arch Gen Psychiatry* 1993; 50: 377–85.
  - 92 Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. *Am J Psychiatry* 2002; 159: 2048–54.
  - 93 Markovitz PJ. Pharmacotherapy of impulsivity, aggression, and related disorders. In: Hollander E, Stein DJ, eds. *Impulsivity and aggression*. Chichester, UK: John Wiley & Sons, 1995; 263–87.
  - 94 Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. *J Clin Psychopharmacol* 1995; 15: 23–29.
  - 95 Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. *Arch Gen Psychiatry* 1986; 43: 680–86.
  - 96 Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. *J Clin Psychiatry* 2001; 62: 849–54.
  - 97 De la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. *Eur Neuropsychopharmacol* 1994; 4: 479–86.
  - 98 Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. *J Clin Psychiatry* 2001; 62: 199–203.
  - 99 Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. *J Clin Psychiatry* 2002; 63: 442–46.
  - 100 Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. *Am J Psychiatry* 2003; 160: 167–69.
  - 101 Schmahl CG, Bohus M. Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung. *Fortschr Neurol Psychiatr* 2001; 69: 310–21.
  - 102 Soloff PH. Psychopharmacology of borderline personality disorder. *Psychiatr Clin North Am* 2000; 23: 169–92.
  - 103 Soloff PH, George A, Nathan RS, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. *J Clin Psychopharmacol* 1989; 9: 238–46.
  - 104 Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. *Compr Psychiatry* 1993; 34: 402–05.
  - 105 Chengappa KNR, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. *J Clin Psychiatry* 1999; 60: 477–84.
  - 106 Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. *J Clin Psychiatry* 2002; 63: 241–44.
  - 107 Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. *Biol Psychiatry* 1999; 46: 1429–35.
  - 108 Cornelius JR, Soloff PH, George A, Ulrich RF, Perel JM. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. *Psychopharmacol Bull* 1993; 29: 333–37.
  - 109 Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. *Arch Gen Psychiatry* 1997; 54: 1081–88.
  - 110 Hollander E, Tracy KA, Swann AC et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. *Neuropsychopharmacology* 2003; 28: 1186–97.
  - 111 Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. *J Affect Disord* 1998; 51: 333–43.
  - 112 Shaffer D, Pfeffer CR, Bernet W et al. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. *J Am Acad Child Adolesc Psychiatry* 2001; 40: 245–51S.
  - 113 Philipsen A, Richter H, Schmahl CG, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. *J Clin Psychiatry* (in press).
  - 114 Bohus M, Landwehrmeyer B, Stiglmayr CE, Limberger MF, Boehme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. *J Clin Psychiatry* 1999; 60: 598–603.
  - 115 Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. *Am J Psychiatry* 1993; 150: 1843–48.
  - 116 Shea MT, Stout R, Gunderson J, et al. Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. *Am J Psychiatry* 2002; 159: 2036–41.
  - 117 Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. *Am J Psychiatry* 2000; 157: 220–28.
  - 118 Coryell W, Endicott J, Maser JD, Mueller T, Lavori P, Keller M. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. *J Affect Disord* 1995; 33: 201–06.
  - 119 Zanarini MC, Frankenburg FR, Hennen J, Silk KR. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. *Am J Psychiatry* 2003; 160: 274–83.
  - 120 Paris J, Zweig-Frank H. A 27-year follow-up of patients with borderline personality disorder. *Compr Psychiatry* 2001; 42: 482–87.
  - 121 Stone MH. The fate of borderline patients: successful outcome and psychiatric practice. New York: Guilford Press, 1990.
  - 122 McGlashan TH. Prediction of outcome in BPD. In: McGlashan TH, ed. *The borderline: current empirical research*. Washington, DC: American Psychiatric Press, 1985; 61–98.
  - 123 Paris J, Brown R, Nowlis D. Long-term follow-up of borderline patients in a general hospital. *Compr Psychiatry* 1987; 28: 530–35.
  - 124 Paris J, Nowlis D, Brown R. Developmental factors in the outcome of borderline personality disorder. *Compr Psychiatry* 1988; 29: 147–50.
  - 125 Plakun EM. Prediction of outcome in borderline personality disorder. *J Personal Disord* 1991; 5: 93–101.
  - 126 Swenson CR, Torrey WC, Koerner K. Implementing dialectical behavior therapy. *Psychiatr Serv* 2002; 53: 171–78.